#1 Clinical Trials Search in Europe

Posdinemab

Posdinemab, also known as JNJ-63733657, is an innovative anti-tau monoclonal antibody currently being studied in clinical trials for early Alzheimer’s Disease. This article delves into the ongoing research, exploring how this drug might potentially slow down the progression of this devastating neurological condition.

Table of Contents

What is POSDINEMAB?

POSDINEMAB, also known as JNJ-63733657, is a promising new medication being studied for the treatment of early Alzheimer’s disease. It is classified as an anti-tau monoclonal antibody, which means it’s a type of biological drug designed to target specific proteins in the brain associated with Alzheimer’s disease[1].

How Does POSDINEMAB Work?

POSDINEMAB works by targeting tau proteins in the brain. In Alzheimer’s disease, tau proteins can become abnormal and form tangles, which are believed to contribute to the decline in brain function. By targeting these tau proteins, POSDINEMAB aims to slow down the progression of the disease and potentially improve cognitive function in patients with early Alzheimer’s disease[1].

Clinical Trial Details

A clinical trial is currently underway to assess the effectiveness and safety of POSDINEMAB. Here are some key details about the study:

  • It’s a randomized, double-blind, placebo-controlled, parallel-group, multicenter study. This means that participants are randomly assigned to either receive POSDINEMAB or a placebo, and neither the participants nor the researchers know who is receiving which treatment[1].
  • The study includes a long-term extension treatment period to evaluate the drug’s effects over time[1].
  • The primary goal is to evaluate how POSDINEMAB affects clinical decline compared to a placebo, using a measure called the iADRS (integrated Alzheimer’s Disease Rating Scale), which assesses both cognition and function[1].

Eligibility Criteria

To participate in the POSDINEMAB clinical trial, patients must meet certain criteria. Some of these include:

  • Age between 55 and 80 years old[1].
  • Diagnosis of early Alzheimer’s disease, with gradual and progressive cognitive decline over at least 6 months[1].
  • Evidence of pathologic tau (abnormal tau protein) on a brain scan[1].
  • Having a designated study partner who can participate and is likely to complete the study with the patient[1].

There are also certain conditions that would exclude a person from participating, such as having severe Alzheimer’s disease or other types of dementia[1].

Potential Benefits

The researchers are studying several potential benefits of POSDINEMAB, including:

  1. Slowing cognitive decline, as measured by various cognitive tests[1].
  2. Improving or maintaining functional status, which refers to a person’s ability to perform daily activities[1].
  3. Slowing the accumulation or spread of tau pathology in the brain, as measured by brain scans[1].
  4. Overall slowing of clinical progression of Alzheimer’s disease[1].

Administration and Dosage

POSDINEMAB is administered as a solution for infusion, which means it’s given directly into the bloodstream through an intravenous (IV) line. The exact dosage and frequency of administration are still being studied in the clinical trial[1].

Data Sharing and Transparency

The company conducting this research, Janssen Pharmaceutical (part of Johnson & Johnson), has committed to sharing data from this study. After the study is completed, researchers can request access to the study data through the Yale Open Data Access (YODA) Project. This commitment to transparency allows other scientists to verify and build upon the findings, potentially leading to further advancements in Alzheimer’s treatment[1].

Aspect Details
Drug Name Posdinemab (JNJ-63733657)
Drug Type Anti-tau monoclonal antibody
Target Condition Early Alzheimer’s Disease
Primary Objective Evaluate effect on clinical decline using iADRS
Administration Intravenous infusion
Study Duration Up to 140 weeks
Key Eligibility Age 55-80, early AD, evidence of pathologic tau
Primary Endpoint Change in iADRS total score at week 104

FAQ

  • What is Posdinemab and how does it work? Posdinemab (JNJ-63733657) is an anti-tau monoclonal antibody. It targets tau proteins in the brain, which are believed to play a role in Alzheimer's disease progression. By targeting these proteins, researchers hope to slow down the clinical decline associated with early Alzheimer's Disease.
  • Who is eligible for the Posdinemab clinical trial? The trial is open to individuals aged 55 to 80 with early Alzheimer's Disease. Participants must show gradual cognitive decline over at least 6 months and have evidence of pathologic tau on a PET scan. They also need a designated study partner to assist throughout the trial.
  • How is the effectiveness of Posdinemab being measured? The primary measure is the change in the iADRS (integrated Alzheimer's Disease Rating Scale) total score after 104 weeks. This scale combines assessments of cognition and function. Other measures include changes in cognitive decline, functional status, and the accumulation of tau pathology in the brain.
  • What are some of the exclusion criteria for the trial? Participants with a Clinical Dementia Rating Global Score of 2 or higher, those with cognitive impairment due to causes other than Alzheimer's, individuals with severe depression, and known carriers of certain genetic mutations associated with Alzheimer's are excluded from the trial.
  • How is Posdinemab administered in the trial? Posdinemab is administered as a solution for intravenous infusion. The exact dosage and frequency of administration are not specified in the provided information, but the treatment period can last up to 140 weeks.

Ongoing Clinical Trials on Posdinemab

  • Study on the Effects of JNJ-63733657 and Florquinitau F18 in Patients with Early Alzheimer’s Disease

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium France The Netherlands Spain Sweden

Glossary

  • Alzheimer's Disease (AD): A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In this case, it targets tau proteins associated with Alzheimer's Disease.
  • Tau Protein: A protein that helps stabilize the internal structure of nerve cells in the brain. In Alzheimer's Disease, tau proteins can become abnormal and form tangles inside brain cells.
  • PET Scan: Positron Emission Tomography, an imaging test that helps reveal how your tissues and organs are functioning.
  • iADRS: Integrated Alzheimer's Disease Rating Scale, a composite measure of cognition and function used to assess the progression of Alzheimer's Disease.
  • ADAS-Cog13: Alzheimer's Disease Assessment Scale-Cognitive Subscale, a test used to measure cognitive function in Alzheimer's patients.
  • ADCS-ADL-MCI: Alzheimer's Disease Cooperative Study-Activities of Daily Living inventory for Mild Cognitive Impairment, a scale used to assess functional abilities.
  • RBANS: Repeatable Battery for the Assessment of Neuropsychological Status, a test used to measure various aspects of cognitive function.
  • CDR-SB: Clinical Dementia Rating Sum of Boxes, a scale used to quantify the severity of symptoms of dementia.
  • GDS-30: Geriatric Depression Scale-30, a screening tool used to identify depression in older adults.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-jnj-63733657-and-florquinitau-f18-in-patients-with-early-alzheimers-disease/